Outset Medical, Inc., a medical technology company, develops a hemodialysis system for dialysis. The company is headquartered in San Jose, California.
| Revenue (TTM) | $117.80M |
| Gross Profit (TTM) | $49.20M |
| EBITDA | $-62.73M |
| Operating Margin | -49.50% |
| Return on Equity | -59.20% |
| Return on Assets | -15.50% |
| Revenue/Share (TTM) | $6.46 |
| Book Value | $6.99 |
| Price-to-Book | 0.88 |
| Price-to-Sales (TTM) | 0.72 |
| EV/Revenue | 0.355 |
| EV/EBITDA | -0.24 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.70% |
| Shares Outstanding | $18.80M |
| Float | $14.78M |
| % Insiders | 5.00% |
| % Institutions | 73.96% |
Volatility is currently contracting
Outset Medical (OM) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Outset Medical, Inc. (OM) Q2 2026 Earnings Call Transcript
Outset Medical NASDAQ: OM reported second-quarter 2026 revenue of $31.6 million, up 1% from a year earlier and 14% sequentially, as the dialysis technology company cited commercial progress, improving margins and a new $40 million refresh agreement with HCA Healthcare.
Shareholders are urged to contact the firm immediately at no cost or obligation, as there may be limited time to enforce your rights. We would handle the matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
SAN JOSE, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the second quarter 2026 after the close of trading on Thursday, August 6, 2026.
SAN FRANCISCO, July 6, 2026 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP advises Outset Medical, Inc. (NASDAQ: OM) investors that the firm is investigating potential legal claims arising from alleged false statements about FDA clearance requirements for one of the company's key products and demand for its dialysis machines. Current shareholders are encouraged to contact the firm here: https://www.classactionlawyers.com/outset.
SAN JOSE, Calif., July 02, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first of-its-kind technology to improve clinical outcomes in dialysis with less cost and complexity (the “Company”), today announced that the Compensation Committee of its Board of Directors approved equity awards under the Company's Inducement Plan, as a material inducement to employment with the Company, for one recently hired executive employee and two recently hired non-executive employees, each of whom was not previously an employee or director of the Company.
Outset Medical (OM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
MONTREAL, June 09, 2026 (GLOBE NEWSWIRE) -- Osisko Metals Incorporated (the "Company" or "Osisko Metals") ( TSX: OM ; OTCQX: OMZNF ; FRANKFURT: 0B51 ) is pleased to announce initial results from the 2026 drill program at the Gaspé Copper Project, located in the Gaspé Peninsula of Eastern Québec. Five drills are currently active on the property, with two additional drills commencing work this month.
Shareholders are urged to contact the firm immediately at no cost or obligation, as there may be limited time to enforce your rights. We would handle the matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on OM and any ticker you trade — then tracks every position and per-strategy win rate.
